

Deborah M Stephens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2006647/publications.pdf>

Version: 2024-02-01

97
papers

2,829
citations

257450

24
h-index

182427

51
g-index

97
all docs

97
docs citations

97
times ranked

3500
citing authors

#	ARTICLE	IF	CITATIONS
1	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	27.0	785
2	PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
3	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019, 3, 1553-1562.	5.2	145
4	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	1.4	130
5	How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 1298-1307.	1.4	108
6	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	2.5	101
7	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	1.6	97
8	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	1.4	86
9	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
10	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	1.4	66
11	Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies. <i>Blood</i> , 2019, 134, 4298-4298.	1.4	58
12	A single-institution retrospective cohort study of first-line <sc>EPOCH</sc> chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	2.5	53
13	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 12-20.	4.9	52
14	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
15	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	1.4	47
16	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2020, 136, 39-40.	1.4	40
17	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 185-217.	4.9	40
18	Ocaratumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. <i>MAbs</i> , 2014, 6, 748-754.	5.2	37

#	ARTICLE	IF	CITATIONS
19	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 622-634.	4.9	33
20	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplantation and Cellular Therapy, 2021, 27, 46-52.	1.2	28
21	Cyclophosphamide, alvocicidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leukemia Research, 2013, 37, 1195-1199.	0.8	26
22	Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Therapeutic Advances in Hematology, 2015, 6, 242-252.	2.5	26
23	Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients. Blood, 2020, 136, 40-41.	1.4	26
24	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, 35, 3201-3211.	7.2	25
25	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1414-1427.	4.9	24
26	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood, 2019, 134, 503-503.	1.4	24
27	Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2011, 46, 84-89.	2.4	23
28	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clinical Cancer Research, 2021, 27, 4814-4824.	7.0	23
29	Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study. Blood, 2016, 128, 638-638.	1.4	23
30	Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia, 2014, 28, 1365-1368.	7.2	19
31	Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology, 2016, 30, 970-4, 980-1, C3.	0.5	19
32	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 2021, 106, 2845-2852.	3.5	18
33	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 2012, 97, 423-427.	3.5	17
34	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. British Journal of Haematology, 2019, 186, 255-262.	2.5	17
35	Acalabrutinib in Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. Blood, 2018, 132, 692-692.	1.4	17
36	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. Blood, 2021, 138, 392-392.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 534-542.	2.3	14
38	Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 16, 217-225.	3.3	14
39	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. <i>Blood</i> , 2021, 138, 1099-1109.	1.4	14
40	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. <i>Clinical Cancer Research</i> , 2022, 28, 3242-3247.	7.0	14
41	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	1.4	13
42	What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 12.	3.0	11
43	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	1.4	10
44	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 12806-12822.	1.8	10
45	Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 303-327.	2.2	9
46	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	2.5	8
47	Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies. <i>Blood</i> , 2015, 126, 2740-2740.	1.4	8
48	MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. <i>Neurology</i> , 2017, 88, 603-604.	1.1	7
49	Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis. <i>Blood</i> , 2019, 134, 780-780.	1.4	7
50	Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 1163-1163.	1.4	7
51	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	1.4	7
52	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6
53	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.	1.4	6
54	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.4	6

#	ARTICLE	IF	CITATIONS
55	Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. <i>Blood</i> , 2022, 140, 401-405.	1.4	6
56	Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1691-1696.	1.4	5
57	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.8	5
58	A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2018, 132, 3136-3136.	1.4	5
59	Brentuximab: is it time for a new "B" in ABVD?. <i>Blood</i> , 2017, 130, 1281-1282.	1.4	4
60	Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 538-541.	1.3	4
61	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study. <i>Blood</i> , 2019, 134, 4310-4310.	1.4	4
62	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021, 138, 529-529.	1.4	4
63	Highs and lows of minimal residual disease in CLL. <i>Blood</i> , 2019, 133, 386-388.	1.4	3
64	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3
65	Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. <i>Blood</i> , 2021, 138, 1973-1973.	1.4	3
66	Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2015, 90, 967-969.	4.1	2
67	Next-Generation Bruton Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2937-2940.	1.6	2
68	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3049-3049.	1.4	2
69	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 4681-4681.	1.4	2
70	Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592). <i>Blood</i> , 2021, 138, 1423-1423.	1.4	2
71	Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study. <i>Blood</i> , 2021, 138, 2631-2631.	1.4	2
72	Is there a role for anti-CD20 antibodies in CLL?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 68-75.	2.5	2

#	ARTICLE	IF	CITATIONS
73	Granulocyte stimulating-colony factor-associated splenic artery rupture. <i>Leukemia and Lymphoma</i> , 2010, 51, 335-337.	1.3	1
74	Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01414.	1.6	1
75	Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation. <i>Blood</i> , 2019, 134, 3990-3990.	1.4	1
76	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	1.4	1
77	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	1.4	1
78	Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine. <i>Blood</i> , 2018, 132, 4426-4426.	1.4	1
79	Debate: What Is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 993-997.	4.9	1
80	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1
81	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	1.4	1
82	Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 49-49.	1.4	1
83	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq1 10.784314rgBT/Ove	1.4	1
84	Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e201-e204.	0.4	0
85	Optimal Frontline Therapy for Young or Fit Patients with Chronic Lymphocytic Leukemia: A Case-Based Discussion. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S45-S48.	0.4	0
86	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. <i>Blood</i> , 2010, 116, 1378-1378.	1.4	0
87	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. <i>Blood</i> , 2013, 122, 2872-2872.	1.4	0
88	Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2013, 122, 4128-4128.	1.4	0
89	The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. <i>Blood</i> , 2015, 126, 831-831.	1.4	0
90	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. <i>Blood</i> , 2016, 128, 2767-2767.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
92	Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis. <i>Blood</i> , 2019, 134, 3982-3982.	1.4	0
93	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553.	1.4	0
94	Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1695-1695.	5.0	0
95	Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 314-317.	0.4	0
96	Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States. <i>Blood</i> , 2021, 138, 1930-1930.	1.4	0
97	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	1.4	0